| Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine FP Polack, SJ Thomas, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... New England journal of medicine 383 (27), 2603-2615, 2020 | 16189 | 2020 |
| Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates EE Walsh, RW Frenck Jr, AR Falsey, N Kitchin, J Absalon, A Gurtman, ... New England Journal of Medicine 383 (25), 2439-2450, 2020 | 2853 | 2020 |
| Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults MJ Mulligan, KE Lyke, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... Nature 586 (7830), 589-593, 2020 | 1882 | 2020 |
| Efficacy of a pneumococcal conjugate vaccine against acute otitis media J Eskola, T Kilpi, A Palmu, J Jokinen, M Eerola, J Haapakoski, E Herva, ... New England Journal of Medicine 344 (6), 403-409, 2001 | 1868 | 2001 |
| Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months SJ Thomas, ED Moreira Jr, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... New England Journal of Medicine 385 (19), 1761-1773, 2021 | 1536 | 2021 |
| Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial MD Tameris, M Hatherill, BS Landry, TJ Scriba, MA Snowden, S Lockhart, ... The Lancet 381 (9871), 1021-1028, 2013 | 1241 | 2013 |
| Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents RW Frenck Jr, NP Klein, N Kitchin, A Gurtman, J Absalon, S Lockhart, ... New England Journal of Medicine 385 (3), 239-250, 2021 | 1070 | 2021 |
| Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age EB Walter, KR Talaat, C Sabharwal, A Gurtman, S Lockhart, GC Paulsen, ... New England Journal of Medicine 386 (1), 35-46, 2022 | 649 | 2022 |
| SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3 AR Falsey, RW Frenck Jr, EE Walsh, N Kitchin, J Absalon, A Gurtman, ... New England Journal of Medicine 385 (17), 1627-1629, 2021 | 398 | 2021 |
| Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine ED Moreira Jr, N Kitchin, X Xu, SS Dychter, S Lockhart, A Gurtman, ... New England Journal of Medicine 386 (20), 1910-1921, 2022 | 333 | 2022 |
| Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and … A de Roux, B Schmöele-Thoma, GR Siber, JG Hackell, A Kuhnke, ... Clinical Infectious Diseases 46 (7), 1015-1023, 2008 | 324 | 2008 |
| RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study EE Walsh, R Frenck, AR Falsey, N Kitchin, J Absalon, A Gurtman, ... Medrxiv, 2020.08. 17.20176651, 2020 | 191 | 2020 |
| An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate … CS Waddington, TC Darton, C Jones, K Haworth, A Peters, T John, ... Clinical Infectious Diseases 58 (9), 1230-1240, 2014 | 163 | 2014 |
| Six Month safety and efficacy of the BNT162b2 Mrna Covid-19 vaccine SJ Thomas, ED Moreira Jr, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... MedRxiv, 2021.07. 28.21261159, 2021 | 142 | 2021 |
| Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults DA Scott, SF Komjathy, BT Hu, S Baker, LA Supan, CA Monahan, ... Vaccine 25 (33), 6164-6166, 2007 | 130 | 2007 |
| Bivalent Omicron BA. 1–Adapted BNT162b2 Booster in Adults Older than 55 Years P Winokur, J Gayed, D Fitz-Patrick, SJ Thomas, O Diya, S Lockhart, X Xu, ... New England Journal of Medicine 388 (3), 214-227, 2023 | 123 | 2023 |
| Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a TC Darton, C Jones, CJ Blohmke, CS Waddington, L Zhou, A Peters, ... PLoS neglected tropical diseases 10 (8), e0004926, 2016 | 98 | 2016 |
| Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine., 2020, 383 FP Polack, SJ Thomas, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... DOI: https://doi. org/10.1056/NEJMoa2034577. PMID: https://www. ncbi. nlm …, 0 | 94 | |
| Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age FM Muñoz, LD Sher, C Sabharwal, A Gurtman, X Xu, N Kitchin, S Lockhart, ... New England Journal of Medicine 388 (7), 621-634, 2023 | 77 | 2023 |
| MVA85A 020 Trial Study Team: Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial MD Tameris, M Hatherill, BS Landry, TJ Scriba, MA Snowden, S Lockhart, ... Lancet 381 (9871), 1021-1028, 2013 | 65 | 2013 |
